Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
The purpose of this study is to learn more about patients with brain tumors understanding of their disease and their communication with their physician. Ultimately, we hope to use these findings to improve communication between patients and their doctors.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prognostic Awareness and Patient-Physician Communication in Malignant Glioma|
- measure prognostic awareness [ Time Frame: 2 years ] [ Designated as safety issue: No ]Prognostic awareness (PA) will be measured using the Chochinov Prognostic Awareness Scale. This scale classifies patients into three categories of awareness: full, limited, or no awareness.
|Study Start Date:||December 2013|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Malignant Glioma patients
This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, except Dr. Eli Diamond's patients and respective caregivers, will be screened for eligibility and willingness to participate in the study.
|Behavioral: surveys and cognitive tests|
Please refer to this study by its ClinicalTrials.gov identifier: NCT02023346
|Contact: Eli Diamond, MD||212-639-7576|
|Contact: Lisa DeAngelis, MD||212-639-7123|
|United States, New York|
|Memoral Sloan Kettering Cancer Center||Recruiting|
|New Yori, New York, United States, 10065|
|Contact: Eli Diamond, MD 212-639-7576|
|Contact: Lisa DeAngelis, MD 212-639-7123|
|Principal Investigator: Eli Diamond, MD|
|Principal Investigator:||Eli Diamond, MD||Memorial Sloan-Kettering Cancer Center|